You are here

MRI Technique Detects Cognitive Decline Before Symptoms Appear

Method could serve as biomarker in early diagnosis, authors say

A magnetic resonance imaging (MRI) technique can detect signs of cognitive decline in the brain even before symptoms appear, according to a new study published online in Radiology. The technique has the potential to serve as a biomarker in the early diagnosis of preclinical dementia, the authors say.

The World Health Organization estimates that dementia affects more than 35 million people worldwide — a number expected to more than double by 2030. Problems in the brain related to dementia, such as reduced blood flow, might be present for years but are not evident because of cognitive reserve, a phenomenon in which other parts of the brain compensate for deficits in one area. Early detection of cognitive decline is critical because treatments for Alzheimer’s disease (AD), the most common type of dementia, are most effective in this early phase.

Researchers recently studied arterial spin labeling (ASL), a promising MRI technique that doesn’t require the injection of a contrast agent. ASL measures brain perfusion, or the penetration of blood into the tissue. “ASL MRI is simple to perform, doesn’t require special equipment, and only adds a few minutes to the exam,” said lead investigator Sven Haller, MD, of the University of Geneva in Switzerland.

The study included 148 healthy elderly participants and 65 people with mild cognitive impairment (MCI). The participants underwent brain MRI and a neuropsychologic assessment — a common battery of tests used to determine cognitive ability.

Of the 148 healthy individuals, 75 remained stable, whereas 73 deteriorated cognitively after 18 months of clinical follow-up. Those who deteriorated had shown reduced perfusion at their baseline ASL MRI exams, particularly in the posterior cingulate cortex, an area in the middle of the brain that is associated with the default-mode network (the neural network that is active when the brain is not concentrating on a specific task). Declines in this network are seen in patients with MCI and are more pronounced in those with AD.

The pattern of reduced perfusion in the brains of healthy individuals who went on to develop cognitive deficits was similar to that of patients with MCI.

“There is a known close link between neural activity and brain perfusion in the posterior cingulate cortex,” Haller said. “Less perfusion indicates decreased neural activity.”

The study results suggest that individuals with decreased perfusion detected with ASL MRI may temporarily maintain their cognitive status through the mobilization of their cognitive reserve, but will eventually develop subtle cognitive deficits.

Previous research conducted with positron emission tomography (PET), the current gold standard for brain-metabolism imaging, found that patients with AD had reduced metabolism in the same area of the brain where the perfusion abnormalities were found using ASL MRI. This finding points to a close link between brain metabolism and perfusion, according to Haller.

ASL MRI has potential as a stand-alone test or as an adjunct to PET for dementia screening, according to Haller. While PET can identify markers of AD in the brain and cerebrospinal fluid, it exposes the patient to radiation. ASL does not expose the patient to radiation and is easy to perform in routine clinical settings, Haller noted.

“ASL might replace the classic yet unspecific fluordesoxyglucose PET that measures brain metabolism. Instead, PET could be done with the new and specific amyloid PET tracers,” he said.

The results also support a role for ASL MRI as an alternative to neuropsychologic testing.

Haller and his colleagues plan to perform follow-up studies on the same group of patients to learn more about ASL and long-term cognitive changes.

Source: Radiological Society of North America; October 7, 2014.

Recent Headlines

Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial